Aoife Brennan/LinkedIn
Jun 12, 2026, 14:27
Aoife Brennan: Ongoing Budo Study Demonstrates Potential in Challenging ITP Population
Aoife Brennan, Board Member at Critical Path Institute (C-Path), President and CEO of Climb Bio, shared a post on LinkedIn:
“Delighted to share data from our ongoing study of budo in ITP today at EHA.
Many of the patients enrolled had a higher number of prior lines of therapy than baseline platelet count which illustrates the need for new treatments that provide durable treatment response.
Immense gratitude to the patients and investigators who are participating and congratulations to the team Climb Bio.”
Stay updated with Hemostasis Today.
-
Sep 11, 2026, 16:09Elad Anter։ A New Map of Atrial Fibrillation Initiation
-
Sep 11, 2026, 15:55Marwa Mostafa: The Paradox of Sideroblastic Anemia
-
Sep 11, 2026, 15:37Empowering Local Stakeholders to Advance Hemophilia Care in Côte d’Ivoire – World Federation of Hemophilia
-
Sep 11, 2026, 15:34Dhargam Aljebouri: A New Milestone for Transfusion Education in Iraq
-
Sep 11, 2026, 15:17Shadi Tabibian: Where Laboratory Precision Meets Clinical Care
-
Sep 11, 2026, 14:58Kevin Land: Connecting Donors to Patients Across the Spectrum of Care
-
Sep 11, 2026, 14:45Jorge Mascaro: The Growing Impact of the UK Aortic Society on Aortic Disease Care
-
Sep 11, 2026, 14:31Hany Ibrahim: Lp(a) Lowering Meets a Critical Test in the Lp(a)HORIZON Trial
-
Sep 11, 2026, 13:35How Non-Factor Therapies Are Changing Hemophilia Care – Seminars in Thrombosis and Hemostasis